Results 161 to 170 of about 617 (209)

Drug‐induced psoriasiform alopecia associated with interleukin‐17 inhibitor therapy

Journal of Cutaneous Pathology, 2021
AbstractDrug‐induced psoriasiform alopecia is an increasingly recognized form of alopecia mostly reported in association with TNF‐alpha inhibitors. However, drug‐induced psoriasiform alopecia in association with IL‐17A inhibitors has not been described.
Timothy L. Tan, Lauren Taglia, Pedram Yazdan   +2 more
openaire   +2 more sources

Treating to Target(s) With Interleukin-17 Inhibitors

Journal of Cutaneous Medicine and Surgery, 2019
Background: The treat-to-target (T2T) strategy has become established in several medical specialties as a key guidance to optimal therapeutic decision making. T2T may be effective in the assessment of the biologic class of agents called interleukin (IL)-17 inhibitors, which are emerging as a safe and effective ...
Charles W, Lynde, Jennifer, Beecker, Jan, Dutz, Cathy, Flanagan, Lyn C, Guenther, Wayne, Gulliver, Kim, Papp, Proton, Rahman, Dalton, Sholter, Gordon E, Searles   +9 more
openaire   +2 more sources

Staphylococcal toxic shock syndrome in a child with interleukin‐17 inhibitor treatment for psoriasis

Pediatric Dermatology, 2020
AbstractA 6‐year‐old girl presented with fever, skin rash, anuria, and conjunctivitis that rapidly progressed to toxic shock syndrome. Following hospital discharge, she developed a staphylococcal abscess on the lower extremity. She had recently received the first two doses of the interleukin‐17 (IL‐17) inhibitor secukinumab for resistant plaque ...
María Sánchez Martín, Irene Amores Hernández, David Argumánez García, Mariano Silva Hernández, Raúl De Lucas Laguna, Francisco Javier Aracil Santos, Rosario López López, María de Ceano‐Vivas La Calle   +7 more
openaire   +2 more sources

Real‐world efficacy and safety of interleukin‐17 inhibitors for psoriasis: A single‐center experience

The Journal of Dermatology, 2020
AbstractWe evaluated the efficacy and safety of interleukin (IL)‐17 inhibitors (IL‐17i) by analyzing 66 patients with psoriasis treated with secukinumab (n = 25), ixekizumab (n = 17) and brodalumab (n = 24) at Kurume University Hospital between December 2014 and June 2019.
Chika Ohata, Bungo Ohyama, Eri Katayama, Takekuni Nakama   +3 more
openaire   +2 more sources

Tinea corporis at the injection site of interleukin-17 inhibitor in psoriasis vulgaris

British Journal of Dermatology
We report a patient with psoriasis vulgaris who developed tinea corporis at the injection site of ixekizumab, an IL-17 inhibitor. This case suggests that local inhibition of IL-17 may reduce dermatophyte resistance, leading to site-specific fungal infections.
Keigo Takase, Takayoshi Komatsu-Fujii, Toshiaki Kogame, Atsushi Otsuka, Kenji Kabashima   +4 more
openaire   +2 more sources

Interleukin-17 Inhibitors

2022
Leena Chularojanamontri, Christopher E.M. Griffiths   +1 more
openaire   +4 more sources

Interleukin‐17 inhibitor, is it safer than tumor necrosis factor inhibitor?

International Journal of Rheumatic Diseases, 2021
Jinxian Huang, Lijun Zhang, James C‐C Wei   +2 more
openaire   +2 more sources

Interleukin 17 Inhibitors

2021
Margot A. Chima, Mark G. Lebwohl
openaire   +1 more source

Candidiasis with interleukin-17 inhibitors

Reactions Weekly, 2021
openaire   +1 more source

Development of alopecia in patients treated with interleukin‐17 inhibitors

Dermatologic Therapy, 2020
Layal Antoury, Nolan Maloney, Kyle Cheng
openaire   +2 more sources